The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib

por Buder, Anna, Hochmair, Maximilian J., Filipits, Martin
Publicado 2020

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

por Yamamoto, Nobuyuki, Mera, Takeshi, Märten, Angela, Hochmair, Maximilian J.
Publicado 2019

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib

por Buder, Anna, Hochmair, Maximilian J., Setinek, Ulrike, Pirker, Robert, Filipits, Martin
Publicado 2020

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response...

por Hochmair, Maximilian J., Buder, Anna, Schwab, Sophia, Burghuber, Otto C., Prosch, Helmut, Hilbe, Wolfgang, Cseh, Agnieszka, Fritz, Richard, Filipits, Martin
Publicado 2018

EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR

por Buder, Anna, Setinek, Ulrike, Hochmair, Maximilian J., Schwab, Sophia, Kirchbacher, Klaus, Keck, Andrea, Burghuber, Otto C., Pirker, Robert, Filipits, Martin
Publicado 2019

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients

por Hackner, Klaus, Buder, Anna, Hochmair, Maximilian J, Strieder, Matthaeus, Grech, Christina, Fabikan, Hannah, Burghuber, Otto C., Errhalt, Peter, Filipits, Martin
Publicado 2021

Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients

por Buder, Anna, Heitzer, Ellen, Waldispühl-Geigl, Julie, Weber, Sabrina, Moser, Tina, Hochmair, Maximilian J., Hackner, Klaus, Errhalt, Peter, Setinek, Ulrike, Filipits, Martin
Publicado 2021

Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients

por Cho, Anna, Untersteiner, Helena, Hirschmann, Dorian, Fitschek, Fabian, Dorfer, Christian, Rössler, Karl, Zöchbauer-Müller, Sabine, Gatterbauer, Brigitte, Hochmair, Maximilian J., Frischer, Josa M.
Publicado 2020

Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy

por Cho, Anna, Untersteiner, Helena, Hirschmann, Dorian, Shaltout, Abdallah, Göbl, Philipp, Dorfer, Christian, Rössler, Karl, Marik, Wolfgang, Kirchbacher, Klaus, Kapfhammer, Irene, Zöchbauer-Müller, Sabine, Gatterbauer, Brigitte, Hochmair, Maximilian J., Frischer, Josa M.
Publicado 2020

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional...

por Miura, Satoru, Jung, Hyun Ae, Lee, Shin Yup, Lee, Seung Hyeun, Lee, Min Ki, Lee, Yong Chul, Hochmair, Maximilian J, Yang, Cheng-Ta, Märten, Angela, Yang, James Chih-Hsin, Popat, Sanjay
Publicado 2022

Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients

por Holzknecht, Arnulf, Illini, Oliver, Hochmair, Maximilian J., Krenbek, Dagmar, Setinek, Ulrike, Huemer, Florian, Bitterlich, Erwin, Kaindl, Christoph, Getman, Vladyslav, Akan, Ahmet, Weber, Michael, Leobacher, Gunther, Valipour, Arschang, Mueller, Michael R., Watzka, Stefan B.
Publicado 2022

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

por Hochmair, Maximilian J., Fabikan, Hannah, Illini, Oliver, Weinlinger, Christoph, Setinek, Ulrike, Krenbek, Dagmar, Prosch, Helmut, Rauter, Markus, Schumacher, Michael, Wöll, Ewald, Wass, Romana, Brehm, Elmar, Absenger, Gudrun, Bundalo, Tatjana, Errhalt, Peter, Urban, Matthias, Valipour, Arschang
Publicado 2020

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

por Chen, Yuanbin, Paz-Ares, Luis, Reinmuth, Niels, Garassino, Marina Chiara, Statsenko, Galina, Hochmair, Maximilian J., Özgüroğlu, Mustafa, Verderame, Francesco, Havel, Libor, Losonczy, György, Conev, Nikolay V., Hotta, Katsuyuki, Ji, Jun Ho, Spencer, Stuart, Dalvi, Tapashi, Jiang, Haiyi, Goldman, Jonathan W.
Publicado 2022

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

por Garassino, Marina C., Gadgeel, Shirish, Speranza, Giovanna, Felip, Enriqueta, Esteban, Emilio, Dómine, Manuel, Hochmair, Maximilian J., Powell, Steven F., Bischoff, Helge G., Peled, Nir, Grossi, Francesco, Jennens, Ross R., Reck, Martin, Hui, Rina, Garon, Edward B., Kurata, Takayasu, Gray, Jhanelle E., Schwarzenberger, Paul, Jensen, Erin, Pietanza, M. Catherine, Rodríguez-Abreu, Delvys
Publicado 2023

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

por Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C. H., Han, Ji-Youn, Hochmair, Maximilian J., Lee, Ki Hyeong, Delmonte, Angelo, García Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander, Gettinger, Scott N., Tiseo, Marcello, Lin, Huamao M., Gupta, Neeraj, Hanley, Michael J., Ni, Quanhong, Zhang, Pingkuan, Popat, Sanjay
Publicado 2020

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

por Gettinger, Scott N., Huber, Rudolf M., Kim, Dong-Wan, Bazhenova, Lyudmila, Hansen, Karin Holmskov, Tiseo, Marcello, Langer, Corey J., Paz-Ares Rodríguez, Luis G., West, Howard L., Reckamp, Karen L., Weiss, Glen J., Smit, Egbert F., Hochmair, Maximilian J., Kim, Sang-We, Ahn, Myung-Ju, Kim, Edward S., Groen, Harry J.M., Pye, Joanna, Liu, Yuyin, Zhang, Pingkuan, Vranceanu, Florin, Camidge, D. Ross
Publicado 2022

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

por Illini, Oliver, Fabikan, Hannah, Swalduz, Aurélie, Vikström, Anders, Krenbek, Dagmar, Schumacher, Michael, Dudnik, Elizabeth, Studnicka, Michael, Öhman, Ronny, Wurm, Robert, Wannesson, Luciano, Peled, Nir, Kian, Waleed, Bar, Jair, Daher, Sameh, Addeo, Alfredo, Rotem, Ofer, Pall, Georg, Zer, Alona, Saad, Akram, Cufer, Tanja, Sorotsky, Hadas Gantz, Hashemi, Sayed M. S., Mohorcic, Katja, Stoff, Ronen, Rovitsky, Yulia, Keren-Rosenberg, Shoshana, Winder, Thomas, Weinlinger, Christoph, Valipour, Arschang, Hochmair, Maximilian J.
Publicado 2022